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OSTEOSARCOMA: MOLECULAR ETIOLOGY, PATHOPHYSIOLOGY, 
CLINICAL PRESENTATION, DIAGNOSIS, AND TREATMENT   
 ALEC LYON SINATRO 
ABSTRACT 
Osteosarcoma is the most common primary malignancy of bone in children and young 
adults, with a worldwide incidence of 3.4 cases per million people per year. For most of 
the 20th century — before the advent of chemotherapy — osteosarcoma was inevitably 
fatal. Despite effective local control achieved through highly invasive and ultimately 
disabling surgical procedures, the vast majority of patients developed pulmonary 
metastasis and most often died in a matter of months. Fortunately, treatment strategies 
have evolved tremendously to include multi-agent adjuvant chemotherapy and various 
forms of limb-sparing surgery that have largely taken the place of amputation. This 
transformation in therapeutic approach materialized gradually, and became firmly 
established in practice during the early 1990s. Not surprisingly, it was around that same 
time that a rather dramatic increase in five-year survival was noted in patients presenting 
with localized disease — jumping from less than 20% prior to the advent of 
chemotherapy, to 60-70% following implementation of the current standard of care. 
However, since this initial period of advancement, very little progress has been made. 
Systemic treatment strategies have barely evolved over the course of the past two 
decades, and the probability of long-term survival thus remains largely unchanged. While 
it is true that roughly two-thirds of patients with localized conventional osteosarcoma 
survive for at least 5 years after receiving multi-modal therapy, the following fact better 
	 v 
reflects the highly-aggressive nature of the disease, and thus also provides a more 
realistic representation of the long-term prognostic implications with which its typically 
associated: the risk of recurrence and metastasis remains markedly elevated following 
complete eradication of the primary tumor. After undergoing surgical resection and 
multiple rounds of both neoadjuvant and postoperative chemotherapy, a significant 
quantity of patients thought to be cured see their malignancy recur, spread, and invade 
distant tissue — at which point, the probability of disease-free survival drops to well 
below 20%. Thus, the need for enhanced, more precisely-targeted mechanisms of 
treatment is indisputable. Accordingly, this work will provide an in-depth description of 
the molecular etiology, pathophysiology, clinical presentation, diagnosis, and treatment 
of osteosarcoma, while also exploring potentially promising novel therapies aimed to 
improve patient outcomes.  
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INTRODUCTION 
 
Osteosarcoma (OS) is the most common primary malignancy of bone in children 
and young adults. It is classically described as a high-grade spindle-shaped neoplasm 
with malignant cells that produce osteoid (Marina 2004). Accounting for roughly 75% of 
all documented cases of OS, Conventional OS (COS) is the most frequent subtype. It is 
of the high-grade, central medullary variety, and most commonly presents in the 
metaphysis of long bones — with the most common skeletal region being the distal 
femur, followed by the proximal tibia, and finally, the proximal humerus (Biazzo 2014). 
Approximately 10–20% of patients will have clinical metastasis at presentation, most 
commonly to the lungs. It most commonly presents during the second or third decades of 
life and is twice as common in males (Kim 2008; Fox 2013).  
The current standard of care for newly diagnosed, localized, COS consists of the 
following interventions, conducted in the specified order: neoadjuvant chemotherapy, 
surgical removal of the primary tumor and all clinically evident signs of metastasis, 
surgical reconstruction of the affected bone, and post-operative adjuvant chemotherapy 
(Harrison 2018). This approach — and specific sub-elements of each aspect — have 
developed out of more than 45 years of basic-scientific and clinical research (Misaghi 
2018). 
Before the introduction of adjuvant chemotherapy in the 1970s, COS was almost 
inevitably fatal. Despite effective local control achieved through surgical resection of the 
primary tumor — then via amputation — the vast majority of patients rapidly developed 
pulmonary metastasis and ultimately died from consequent respiratory failure. The root 
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cause was later determined to be microscopic sub-clinical metastases present at the time 
of diagnosis (Carrle 2006). If already present in pulmonary tissue at the time of surgery, 
left untreated, metastatic cells would continue to proliferate and result in rapid death. If 
present in extra-pulmonary sites distant from the primary tumor, left untreated, metastatic 
cells would rapidly make their way to the lungs, proliferate, and destroy. Either way, the 
result of seemingly effective local control was constant. As put simply by a renowned 
surgical oncologist during a 1920s conference on bone cancer: “If you do not operate 
they die; if you do operate they die just the same” (Cade 1955; Carrle 2006). Hence, the 
primary goal of adjuvant chemotherapy is to eliminate systemic micrometastases. 
Together, surgery and adjuvant chemotherapy serve to eradicate the primary tumor, 
clinically detectable metastases, and sub-clinical microscopic metastases — as 
chemotherapy alone has proven unable to effectively eliminate the former two (Jaffe 
2002; Carrle 2006). Current use of this multi-modal approach results in disease-free 
survival of 60-70% of patients diagnosed with primary, localized COS — as it has for 
roughly the past two decades. Since these early advances, treatment strategies have failed 
to improve outcomes in the roughly 30% of patients with negative prognostic indicators, 
for whom disease-free survival rates remain markedly depressed following initial 
treatment (Misaghi 2018). There is a clear need to address this disparity in efficacy of 
therapy through novel, more-precisely targeted methods of treatment.  
In the first portion of this thesis, general background information regarding 
classification, grading, and staging of OS will be provided. Next, the molecular genetics 
and pathophysiology of OS — in addition to corresponding targeted therapies currently 
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under development — will be discussed. Then, information pertaining to the 
epidemiology, skeletal localization, histopathology, clinical presentation, and diagnosis 
of the most common subtype of OS — COS — will be provided. The remainder of the 
thesis will then focus on the interventions that comprise the current, multi-modal standard 
of care, the pathways that hastened their development, and ongoing efforts being made to 
improve outcomes in poor responders. Finally, conclusions and future directions will be 
considered.  
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OSTEOSARCOMA 
 
CLASSIFICATION, GRADE, AND STAGE  
 
Osteosarcomas are classified according to anatomical location, cell type, and 
tumor grade (Biazzo 2014). In terms of anatomical location, the World Health 
Organization divides OS histologically into central medullary (within the central canal of 
the affected bone) and surface tumors (Misaghi 2018). Most are located in the central 
medullary space of long bones. (Fox 2013). All osteosarcomas contain osteoid, but to 
varying degrees. The majority of tumors also contain differing quantities of cartilage and 
fibrous tissue. They are thus classified as osteoblastic, chondroblastic, or fibroblastic, 
depending on the cell type that comprises greater than 50% of the malignancy — with 
respective prevalence ranging from 50 to 80%, 5 to 25%, and 7 to 25% (Fox 2013).  
Enneking’s Classification is the most commonly utilized system for staging 
osteosarcomas. It categorizes according to grade and local anatomic extent, without 
regard for origin of location within the affected bone or predominant cell type comprising 
the tumor (Enneking 1980). Histological grading is essentially based on the degree of 
cellular atypia present within the malignancy. Intuitively, it is performed using the area of 
the tumor with the highest mitotic rate and greatest degree of anaplasia. Local anatomic 
extent pertains to whether or not the primary tumor extends through the cortex of the 
affected bone from its site of origin (Fox 2013). 
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Table 1. Enneking’s Classification of Osteosarcoma. G1: low-grade; G2: high-grade; T1: 
intracompartmental; T2: extracompartmental; M0: no distant metastases; M1: distant metastases. 
Adapted from (Biazzo 2014).  
 
Stage Grade Site Metastases Definition  
IA G1 T1 M0 Low-grade, intracompartmental, no distant metastases   
IB G2 T2 M0 Low-grade, extracompartmental, no distant metastases  
IIA G1 T1 M0 High-grade, intracompartmental, no distant metastases  
IIB G2 T2 M0 High-grade, extracompartmental, no distant metastases  
IIIA-B G1-G2 T1-T2 M1 
Either low or high-grade, intra or 
extracompartmental, distant 
metastases  
 
 
MOLECULAR ETIOLOGY  
 
The majority of OS cases develop sporadically, and contain complex genomic 
profiles (Perry 2014). Fortunately, recent refinement of next generation sequencing has 
facilitated enhanced characterization. Typically, these tumors present with a higher 
somatic mutation rate than the vast majority of other pediatric cancers, suggesting a 
unique mechanism of transformation (Lawrence 2013; Perry 2014). Significant genomic 
structural instability is denoted by a high frequency of complex chain rearrangements 
often involving multiple chromosomes and deletion bridges, which indicate large 
segments of deletion at fusion junctions (Perry 2014). Inactivation of the tumor protein 
p53 gene (TP53) — which has proven to be the most common alteration in OS tumors — 
is thought to play a role in this genomic instability, as the normal protein product 
increases in response to DNA damage, halts progression through the cell cycle, induces 
DNA repair, and prompts apoptosis when damage is deemed irreparable (Biazzo 2014). 
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However, whether the genomic instability and prevalence of localized hypermutation 
found in OS is a direct result of alterations in this vital tumor suppressor, or a mechanism 
of osteosarcomagenesis in and of itself, has yet to be elucidated (Perry 2014). What is 
known for certain, though, is that rearrangements with breakpoints near TP53 occur with 
great frequency, and both the gene and its regulatory region commonly serve as fusion 
partners with distant genomic regions (Perry 2014). Additionally, amplification of the 
mouse double minute 2 homolog (MDM2) and constitutive photomorphogenesis 
signalosome complex subunit 3 (COPS3) genes are commonly noted. These genes 
encode proteins that serve as negative regulators of p53 — the protein product of TP53 
— stability, and target p53 for proteasome-mediated degradation (Henriksen 2003, 
Lonardo 1997; Miller 1996; Perry 2014). Thus, when upregulated, they provide an 
indirect means of TP53 inactivation. Mutations in the retinoblastoma protein gene (RB1) 
are also characteristic of OS (Perry 2014). Similar to TP53, the protein product of RB1 
— pRb — serves as a cell cycle regulator (Biazzo 2014). Inactivation therefore facilitates 
unchecked and often aberrant progression through the cell cycle, and ultimately, 
uncontrolled proliferation.  
Recently, extensive focus has been placed on elucidating the role of 
phosphatidylinositol 3 kinase (PI3K) / protein kinase B (Akt) / mammalian target of 
rapamycin (mTOR) pathway genes in the development of OS. Under normal conditions, 
this pathway is linked to the activation of particular receptor tyrosine kinases (RTKs) and 
their associated, downstream intracellular protein kinases — which, together (along with 
their complementary extracellular ligands), promote cell growth, proliferation, survival, 
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and the sort of cytoskeletal rearrangements necessary for invasion and metastasis (Osaka 
2014). A study conducted by Perry et al — which presented the first comprehensive next 
generation sequencing of OS, in combination with a functional genomic screen in a 
genetically defined OS mouse model — showed that OS cell line proliferation and tumor 
formation are highly-dependent on activation of the PI3K and mTOR genes (Perry 2014). 
It also identified other means of PI3K/mTOR pathway activation. For example, 
inactivating mutations in the phosphatase and tensin homolog gene (PTEN) — which 
codes for a negative regulator of the pathway — were commonly noted, as were 
activating mutations in a number of RTK genes. Normally, binding of specific ligands to 
particular RTKs results in activation of numerous pro-growth pathways. Thus, mutations 
that lead to RTK constitutive activation commonly promote neoplastic proliferation — as 
has now been determined to be the case for OS (Osaka 2014; Perry 2014). The study also 
identified an alternate means of PTEN inactivation. It determined that micro RNA 221 — 
known to commonly be expressed at abnormally high levels in OS — targets PTEN for 
degradation, thus decreasing apoptosis, increasing cell survival, and contributing to the 
induction of chemotherapeutic resistance in models of OS (Zhao 2013; Perry 2014). The 
study also demonstrated the in vivo efficacy of PI3K/Akt/mTOR inhibitors in 
suppressing proliferation and promoting apoptosis in xenograft cell lines of OS. Once 
compiled, the above findings — obtained through a combination of pathway analysis and 
clinical interpretation of mutated genes, a comparative oncology approach, and a 
genomic screen — led Perry et al to implicate the PI3K/Akt/mTOR pathway as a 
potentially unifying vulnerability with tremendous clinical promise (Perry 2014). In a 
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subsequent section, the role of this pathway in osteosarcomagenesis, and its potential as a 
target for therapeutic intervention, will be discussed in far greater detail. 
 
Table 2. Typical Genomic Profile of OS: Summary. Content adapted from (Brown 
2018; Zheng 2018; Perry 2014).  
Significant inter and intra-tumoral heterogeneity (high degree of cancer cell ploidy) 
High somatic mutation rate and kataegis (prevalence of localized hypermutation, 
particularly involving C to T and/or C to G mutations within closely spaced T-C-X 
trinucleotide sequences)  
Chains of complex chromosomal rearrangements with large segments of deletion 
commonly noted at fusion junctions 
Inactivating alterations in TP53 and RB1 genes  
Activating alterations in PI3K/Akt/mTOR pathways, secondary to alterations in 
pathway components, with frequent loss of PTEN (more generally, overall dependence 
on PI3K/Akt/mTOR pathway upregulation)  
 
MOLECULAR PATHOPHYSIOLOGY: PROTEIN KINASE INVOLVEMENT  
Numerous protein kinases have been found to be highly expressed, over-activated, 
and correlated with more severe prognoses in patients with OS, thus suggesting their 
utility as targets for pharmacological exploitation. Both transmembrane protein kinases 
(receptor tyrosine kinases) and downstream, intracellular protein kinases have been 
implicated (Osaka 2014). The following sections will thus discuss their role in the 
development and progression of OS, and their potential as targets for therapeutic 
intervention.  
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MOLECULAR PATHOPHYSIOLOGY: INITIATION OF INTRACELLULAR 
SIGNALING PATHWAYS VIA RECEPTOR TYROSINE KINASE ACTIVATION 
Receptor tyrosine kinases (RTKs) have a transmembrane structure, consisting of 
an extracellular ligand binding domain and intracellular tyrosine kinase (TK) domain. 
Following ligand binding, activation via autophosphorylation occurs. This increases the 
affinity of the TK domain for intracellular substrates, and enhances its ability to 
phosphorylate and thus activate downstream signaling pathways associated with cell 
growth, proliferation, survival, and migration (Osaka 2014). Overexpression and 
constitutive activation of particular RTKs — resulting from mutations in their respective 
genes and/or associated regulatory regions — have been implicated in the development 
and progression of OS (Hassan 2012). The following sections will thus describe the 
involvement of two major RTKs— insulin-like growth factor receptor type 1 (IGF-1R) 
and epidermal growth factor receptor (EGFR) — in osteosarcomagenesis, in addition to 
the use of selective small molecule inhibitors and monoclonal antibodies as a means to 
decrease their expression and extent of activation (Osaka 2014; Hassan 2012).  
 
MOLECULAR PATHOPHYSIOLOGY: IGF-1R and EGFR AS THERAPEUTIC 
TARGETS 
IGF-1R is an RTK that binds ligands such as insulin-like growth factor 1 (IGF-1) 
and insulin-like growth factor 2 (IGF-2) — soluble peptides that stimulate cellular 
growth, maturation, and proliferation (Osaka 2014). Upon binding, the receptor’s 
intracellular TK domain becomes activated via autophosphorylation, ultimately resulting 
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in the subsequent phosphorylation and activation of downstream substrates — mainly, 
insulin receptor substrate protein 1 (IRS-1). Activated IRS-1 then triggers a number of 
signal transduction cascades, some of which serve to promote cell proliferation and 
prevent apoptosis, and have thus been implicated in osteosarcomagenesis — for example, 
the aforementioned PI3K/Akt/mTOR pathway that will be discussed in greater detail 
(Kuijjer 2013; Perry 2014; Osaka 2014).  
 As previously mentioned, IGF-1R is commonly overexpressed in OS, and is 
associated with poor prognosis and an increased risk of metastasis (Wang 2012). 
Significant focus has thus been placed on the development of small molecule inhibitors 
— more specifically, tyrosine kinase inhibitors (TKIs) — and monoclonal antibodies 
(mAbs), designed to downregulate expression and decrease activation of the receptor 
(Osaka 2014). A recent study, for example, reported suppression of OS cell growth in 
vitro and reduced tumorigenicity in vivo following lentivirus-mediated RNAi 
downregulation of IGF-1R expression (Wang 2009). Downregulation was also found to 
arrest the OS cells in the G0/G1 phase of the cell cycle, and ultimately induced apoptosis 
through activation of Caspase-3 (Wang 2009). Linsitinib — a small molecule inhibitor of 
IGF-1R — inhibited proliferation of three out of four OS cell lines (Kuijjer 2013). 
Unfortunately, the drug is associated with significant toxicity, as it has virtually the same 
affinity for the insulin receptor as it does for IGF-1R (Osaka 2014). It would thus have to 
yield significant improvements in phase II and III clinical trials for high-risk OS patients 
— for example, those presenting with recurrent disease or overt metastasis — in order to 
be incorporated into treatment protocols of eligible patients. Cyclolignan 
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picropodophyllin, on the other hand, selectively inhibits IGF-1R, and thus the 
PI3K/AKT/mTOR pathway (Osaka 2014). A recent study proved its efficacy in doing so 
in both chemotherapy-sensitive and chemotherapy-resistant OS cell lines (Duan 2009). 
Based on the success of these promising pre-clinical studies, it is currently under 
investigation in a number of phase II clinical trials (Osaka 2014).  
 mAbs directed toward IGF-1R are gaining ground as a potentially viable option 
for the treatment of OS. Cixutumumab — a human IgG mAb — inhibits overactivation 
of IGF-1R by preventing binding of IGF-1 and 2 ligands (Osaka 2014). In a multicenter, 
phase II clinical trial for patients with chemotherapy-resistant bone and soft tissue 
sarcomas, Cixutumumab was administered in combination with Temsirolimus — a 
selective mTOR inhibitor (Schwartz 2013). Previous studies have shown that mTOR 
inhibitors alone have the potential to result in paradoxical activation of Akt — a protein 
kinase that, when activated, interacts with various downstream substrates associated with 
cell growth, proliferation, and survival (O’Reilly 2006). Akt activation is central to the 
afore-mentioned biological processes induced by PI3K/mTOR activation. This 
paradoxical activation of Akt may thus explain the failure of numerous mTOR inhibitors 
in halting sarcoma cell proliferation and growth (Okuno 2011). Interestingly, IGF-1R 
inhibition has been found to suppress mTOR-mediated Akt activation, thus sensitizing 
sarcoma cells to mTOR inhibition — hence, the underlying thinking for this multi-drug 
approach. Three of the twenty-four OS patients included in the study experienced a 
partial response (Schwartz 2013). Thus, additional clinical trials with a larger sample size 
will be necessary to fully evaluate the efficacy of this combination therapy for patients 
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with OS. SCH717454 is a neutralizing anti-IGF-1R antibody that is currently being 
evaluated in a phase II clinical trial for patients with refractory OS (Osaka 2014). In a 
preclinical study, it yielded a complete response in four out of six OS xenograft models 
(Kolb 2008). While these studies are promising, in vivo efficacy is yet to be determined.    
 Much like IGF-1R, EGFR is an RTK that, when activated, induces downstream 
activation of numerous signaling cascades tied to cell proliferation, survival, and 
metastasis — again, including the afore-mentioned PI3K/AKT/mTOR pathway on which 
OS cells are thought to depend (Osaka 2014). To date, a number of studies have reported 
overexpression of EGFR in 40-81% of OS tumors sampled; however, controversy 
remains surrounding the correlation between overexpression and severity of prognosis in 
vivo (Oda 1995; Do 2009; Osaka 2014). Additionally, small molecule inhibitors and 
mAbs specific to EGFR have thus far proven ineffective in halting the progression of OS 
cell lines in vitro, calling further into question the role of these RTKs in 
osteosarcomagenesis (Lee 2012). Nevertheless, because it has been confirmed that OS 
cells express — and in fact, often overexpress — EGFR, many researchers continue to 
perceive this RTK as a viable target for pharmacological exploitation. In their minds, 
with a large number of EGFR-specific TKIs yet to be tested in the context of OS, 
extensive effort must still be invested before this potential therapeutic target can be 
disregarded (Osaka 2014; Lee 2012).  
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MOLECULAR PATHOPHYSIOLOGY: INTRACELLULAR SIGNAL 
TRANSDUCTION 
To reiterate — in the context of both normal and neoplastic cell growth, 
proliferation, and migration — binding of a variety of ligands to their complimentary 
RTKs ultimately results in activation of one or more of the following major signaling 
pathways: PI3K/AKT/mTOR, MAPK, JAK/STAT (Osaka 2014). As discussed in an 
earlier section, mutations in genes encoding protein components of these pathways are 
characteristic of OS. Such alterations induce inactivation of negative regulators, 
constitutive activation and/or upregulation of positive regulators, and thus ultimately, 
uncontrolled cell growth, proliferation, and metastasis (Perry 2014; Osaka 2014). 
Because recent literature specifically implicates dysregulation of the PI3K/AKT/mTOR 
pathway as a likely unifying event in osteosarcomagenesis, the following section will 
describe this particular signaling cascade —and its potential to be exploited for targeted 
therapy — in great detail.  
 
MOLECULAR PATHOPHYSIOLOGY: PI3K/Akt/mTOR PATHWAY AS A 
THERAPEUTIC TARGET  
PI3K is a soluble, intracellular kinase that is primarily activated by RTKs 
including IGF-1R and EGFR (Osaka 2014). Upon activation, PI3K phosphorylates 
membrane bound phosphatidylinositol-4,5-bisphosphate (PIP2), forming 
phosphatidylinositol-3,4,5-trisphosphate (PIP3). Formation of the latter results in 
recruitment of Akt — a soluble, intracellular kinase — to the cell membrane, followed by 
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its activation (Osaka 2014). Through subsequent interaction with a number of 
downstream proteins, activated Akt promotes cell growth, proliferation, and survival 
(Cantley 2002; Osaka 2014). PTEN regulates activation of Akt and its associated 
biological processes through dephosphorylation of PIP3 (Osaka 2014). Put simply, PTEN 
shuts off the pathway by converting PIP3 back to PIP2, resulting in inactivation of Akt 
and the many downstream substrates with which it interacts (Figure 1).  
 
Figure 1. PI3K/Akt/mTOR Signaling Pathway and Potential Target Sites for 
Pharmacologic Intervention. Details of the cascade provided in the text. LY294002, 
XL147 = PI3K inhibitors tested in pre-clinical, in vivo OS xenograft models. MK2206 = 
Akt inhibitor tested in pre-clinical, in vivo OS xenograft models. Adapted from (Osaka 
2014).  
 
 In OS, inactivating mutations in PTEN result in constitutive activation of the 
pathway, and thus uncontrolled cell proliferation, survival, migration, and metastasis 
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(Freeman 2008; Osaka 2014). Activating mutations in PIK3CA — the region of the PI3K 
gene that encodes the protein’s catalytic subunit — also serve as a common means of 
constitutive pathway activation (Perry 2014; Osaka 2014). When altered in this way, the 
catalytic subunit of PI3K remains active in the absence of RTK activation. Membrane 
bound PIP3 thus remains as such, in its activated form, resulting in the constitutive 
activation of Akt and its downstream substrates that induce the afore-mentioned 
biological processes. As will soon be discussed in greater detail, activated PI3K also 
activates mTOR — a soluble serine/threonine kinase that activates numerous downstream 
substrates, including Akt (Osaka 2014). Thus, activating mutations in PI3K yield 
constitutive activation of Akt — and thus perpetual growth and proliferation — through 
distinct but redundant mechanisms. Numerous PI3K inhibitors have proved effective in 
halting cell proliferation and slowing tumor formation in pre-clinical models of OS, but 
their efficacy in treating human OS patients has yet to be fully evaluated (Gong 2012; 
Perry 2014).  
 mTOR exists in the form of two distinct multi-protein complexes —mTORC1 and 
mTORC2. Though directly stimulated by distinct intracellular signals, both ultimately 
become activated following activation of PI3K. Activated PI3K directly activates 
mTORC2, which — as mentioned above — directly activates Akt. mTORC2 thus plays a 
significant role in cell growth, proliferation, and survival through its interaction with Akt 
(Osaka 2014). It thus also indirectly stimulates activation of mTORC1, as activated Akt 
inhibits the mTORC1 repression factor tuberous sclerosis complex (TSC). Without Akt-
mediated inhibition, activated TSC inhibits the GTP binding protein Rheb, which is 
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responsible for mTORC1 activation. With inhibition of TSC, Rheb and thus mTORC1 
are activated. Activated mTORC1 then induces protein translation — and thus cell 
growth and proliferation — through phosphorylation and activation of downstream 
substrates (Figure 2) (Saxton 2017; Osaka 2014).  
 
Figure 2. mTOR Signaling Pathway and Potential Target Sites for Pharmacologic 
Intervention. Details of the cascade provided in the text. Sirolimus, Temsirolimus, 
Ridaforolimus, Everolimus = mTORC1 inhibitors tested in clinical trials. Adapted from 
(Osaka 2014).  
 
 The previously discussed study conducted by Perry et al. demonstrated that 
growth and proliferation of OS cell lines are dependent upon activation of mTOR (Perry 
2014). A separate study also showed that overexpression of mTOR is associated with 
poor outcomes in OS patients (Zhou 2010)  
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 A number of mTOR inhibitors have showed significant clinical promise. 
Rapamycin, for example — a small molecule inhibitor that binds to and directly 
inactivates mTORC1 — inhibited proliferation of OS cells in vitro and in xenografts of 
OS cell lines in vivo (Houghton 2008; Osaka 2014). A number of clinical trials are 
currently underway to determine its efficacy in human subjects (Osaka 2014). 
Ridaforolimus — another mTORC1-selective inhibitor — has now undergone extensive 
pre-clinical and clinical evaluation in the context of a number of different sarcomas, 
including OS. For example, it initially proved effective in inhibiting cell growth and 
proliferation in OS xenograft models (Rivera 2011; Demetri 2013). It then showed 
clinical benefit in patients with advanced bone and soft tissue sarcomas in phase I and II 
clinical trials, warranting further clinical evaluation (Chawla 2012). Finally, in a 
randomized phase III clinical trial, administration of the inhibitor proved to reduce the 
risk of disease progression and death by 28% in patients with advanced soft tissue and 
bone sarcomas who had previously received the typical chemotherapeutic regimen. 
However, the study’s authors noted that the absolute magnitude of that statistically 
significant improvement was actually quite small, due to the fact that the progression of 
disease proved far more rapid than expected throughout the entire study population. 
Additionally, though the overall sample size was relatively large, and the study 
adequately powered, the proportion of patients with high-grade OS was small, as a 
variety of bone and soft tissue sarcomas were included (Demetri 2013). Additional 
clinical evaluation specific to patients with OS will thus be necessary to determine true 
utility. Everolimus — an orally available rapamycin and ridaforolimus analogue — also 
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showed clinical promise in a phase II trial geared toward bone and soft-tissue sarcoma 
patients that responded poorly to traditional chemotherapy (Yoo 2013). However, once 
again, the proportion of included patients with high-grade OS was small; thus, additional 
phase II clinical trials specific to OS are now underway (Yoo 2013; Osaka 2014).  
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CONVENTIONAL OSTEOSARCOMA 
 
 
SUBTYPES, EPIDEMIOLOGY, AND SKELETAL LOCALIZATION  
 
Accounting for roughly 75% of all documented cases of OS, COS is the most 
frequent primary malignant tumor of bone. In terms of its sub-classification as a form of 
OS, it is of the high-grade, central medullary variety (Biazzo 2014). It most commonly 
presents during the second or third decades of life and is twice as common in males (Kim 
2008; Fox 2013). Despite a tendency to afflict young adults, the disease shows a bimodal 
age distribution, with a second peak observed in adults over the age of sixty; however, 
such cases are most often secondary to separate conditions, such as Paget’s disease, 
irradiated bone, chronic osteomyelitis, bone infarct, and de-differentiated 
chondrosarcoma — and are thus not classified as conventional, primary OS (Biazzo 
2014; Mirabello 2009). Regardless of age at onset, the vast majority of cases are staged 
II-B at presentation, as penetration through the cortex typically occurs early in 
tumorigenesis (Biazzo 2014).  
Though COS has the ability to originate in any one region of the skeleton, there 
are particular areas in which it is especially common (Figure 3). It occurs in the distal 
femur in 40-70% of cases, the proximal tibia in 16-25% of cases, and the proximal 
humerus in 5-15% of cases (Kim 2008; Kaste 2004). 
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Figure 3. Sex Prevalence, Age Prevalence, and Skeletal Localization of COS. 
Adapted from (Biazzo 2014).   
 
Within the long bones, metaphyseal tumors (i.e., those occurring in the metaphysis, the 
region of bone separating the epiphysis — the very end of the bone — from the diaphysis 
— the central shaft of the bone) comprise roughly 90% of cases. Isolated diaphyseal and 
epiphyseal tumors comprise less than 10% and 1% of cases, respectively (Fox 2013). 
Though isolated epiphyseal regions are particularly rare, aggressive forms of COS often 
extend from their common metaphyseal origin, through the epiphyseal growth plate, and 
into the epiphysis, where additional neoplastic invasion ensues (Figure 4) (Suresh 2007; 
Fox 2013).  
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Figure 4. COS of the Distal Femur with Focal Destruction of the Epiphyseal Plate. 
Approximate position of epiphyseal plate denoted by blue lines in figure on left. Slight 
remnant of epiphyseal plate within center of blue box on right. Compare with clearly 
visible epiphyseal plate in Figure 5. The tumor has clearly breached the cortex (outlined 
by red lines, where possible), producing the evident soft tissue mass encircling the native 
bone. With this specimen, it is not possible to precisely demarcate the distal metaphyseal-
diaphyseal boundary. The distal epiphysis, however, is the region of bone distal to the 
former location of the epiphyseal plate (area denoted by yellow diagonals). Adapted from 
(Fournet n.d.). 	
 
In other cases, however, the immature epiphyseal plate acts as a barrier, preventing 
migration of malignancy in to the proximal or distal-most aspect of the bone (Figure 5) 
(Uduma et al. 2017; Suresh 2007; Fournet n.d.).  
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Figure 5. COS of the Proximal Femur without Destruction of the Epiphyseal Plate. 
Note the epiphyseal plate (outlined by yellow lines in bottom-most specimen) acting as a 
barrier between the neoplastic metaphysis and normal epiphysis. Taken from (Fournet 
n.d.) 
 
HISTOPATHOLOGY  
COS is thought to arise from the uncontrolled proliferation of intraosseous 
mesenchymal stem cells that follow a pattern of either osteoblastic, chondroblastic, or 
fibroblastic differentiation (Biazzo 2014). As previously stated, in all forms, the 
malignant cells deposit some degree of immature osteoid matrix (Biazzo 2014; Brown 
2018; Zheng 2018). The osteoblastic variety has osteoid or mineralized bone as the 
predominant form of matrix; the chondroblastic variety has a chondroid matrix; and the 
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fibroblastic variety has a matrix consisting of densely packed, malignant spindle cells 
with scant osteoid present. However, despite these differences, recent studies have 
indicated that no significant differences in clinical outcomes exist amongst these subtypes 
(Ozaki 2002). 
  
A                                                            B 
 
        C 
 
Figure 6. Histopathology of COS Subtypes. (A, TOP LEFT): Osteoblastic COS 
dominated by the production of extracellular bone matrix. Immature bone deposition is 
seen in a pattern resembling lace into which malignant cells are interwoven. (B, TOP 
RIGHT): Chondroblastic COS dominated by cellular hyaline cartilage with scant osteoid 
present in the upper right corner. (C, BOTTOM): Fibroblastic COS dominated by 
spindle cells resembling atypical fibroblasts, with very little osteoid present. Adapted 
from (Klein 2006).  
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Thus, from a broad histological perspective, COS is characterized by sarcomatous tissue 
composed of neoplastic cells that produce osteoid matrix and bone in a highly anarchical 
architecture. Typically, the constituent cells display some or all of the following 
characteristic features of high-grade malignancy: hypertrophy, atypia, hyperchromia, 
frequent and atypical mitotic figures (Biazzo 2014).  
  
 
GROSS APPEARANCE  
As previously described, COS typically presents as a high-grade tumor of central 
medullary origin, most commonly found in the metaphyseal region of long bones. Due to 
its aggressive nature, it has usually penetrated the cortex by the time of diagnosis, 
producing an associated extramedullary mass of intermixed osteoid and soft tissue 
matrix, which often encircles a large area of bone (Figures 7 and 8) (Fournet n.d.). 
Macroscopically, the tumoral tissue tends to be whitish or rose-colored, and of both hard 
and soft consistency due to the inconsistent and sporadic production of osteoid by 
neoplastic cells. As ossification increases, vascularity decreases, so that harder areas with 
a greater concentration of osteoid or mineralized bone appear whiter than those 
dominated by a soft tissue matrix (Figure 8). Central areas of the tumor tend to be more 
ossified and thus less vascularized than peripheral regions. Additionally, cystic cavities 
and areas of both hemorrhage and necrosis are commonly identified upon gross 
inspection (Figures 7 and 8) (Biazzo 2014).   
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Figure 7. COS of the Proximal Femur with Cortical Breach and Associated Soft 
Tissue Mass. Areas of aneurysmal bone cyst formation, hemorrhage, and necrosis extend 
through nearly the entire length of the femur. Adapted from (Fournet n.d.) 
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Figure 8. COS of the Distal Femur with Cortical Breach. The tumor has penetrated 
both the medial and lateral cortex (outlined in blue). It has not surpassed the epiphyseal 
plate. Note the presence of extramedullary, neoplastic osteoid and soft tissue (everything 
outside of the blue borders). Adapted from (Biazzo 2014).  
 
CLINICAL PRESENTATION AND SYMPTOMS  
Patients with COS typically present with pain at the primary site of the tumor. In 
general, small lesions cause little to no pain (Durfee 2016). However, as they grow, and 
begin to significantly disrupt osseous architecture, pain becomes evident and, eventually, 
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severe. Thus, in most cases, symptomatic onset and diagnosis do not take place until 
months after the initial stages of tumor development, once significant growth has taken 
place. At presentation, the pain is often described as dull and aching, permeating from 
deep to superficial. It is commonly characterized as both persistent — present at rest and 
during sleep — and exacerbated by physical activity (Moore 2014).  
 
DIAGNOSIS 
The correct diagnosis and subsequent classification of COS should be achieved 
through a combination of clinical, radiographic, and, ultimately, histologic evaluation. 
Physical exam findings often reveal a tender and firm soft tissue mass, restricted joint 
motion, pain upon palpation, and localized warmth surrounding the primary tumor 
(Durfee 2016). Roughly 5-10% of patients present with a secondary fracture as a first 
sign of disease (Scully 2002). Many of the traditional hallmarks of cancer used as 
diagnostic clues — weight loss, malaise, and fever, for example — are typically not 
present, except in the case of highly advanced COS. Additionally, laboratory values have 
not been shown to be helpful (Moore 2014). Imaging thus plays a vital role in diagnosis, 
and should be immediately called upon if physical examination yields any indication of 
COS (Biazzo 2014; Durfee 2016; Moore 2014).  
 At presentation, the majority of conventional osteosarcomas are evident on plain 
radiographs, which typically demonstrate what has classically been described as a moth-
eaten appearance of the affected bone, with variable amounts of cloudy mineralized 
matrix, intermixed with areas of bone resorption (Moore 2014; Fu 2017; Fox 2013; 
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Biazzo 2014). In other words, because these tumors destroy normal bone through 
neoplastic invasion, while simultaneously depositing new osteoid, both lucent and 
sclerotic features are typically evident (Biazzo 2014). Additionally, because most tumors 
will have breached cortex and elevated periosteum off bone by the time of diagnosis, 
subperiosteal bone deposition — which typically appears in a characteristic formation 
known as Codman’s Triangle (Figures 9 and 10) — serves as a reliable indicator of 
COS; as does its sunburst appearance that stems from neoplastic bone being laid down 
perpendicular to the direction of the shaft (Figure 10) (Moore 2014; Fox 2013; Fu 2017; 
Biazzo 2014).  
 
Figure 9. Plain Radiograph Showing COS of the Distal Femur with Codman’s 
Triangle. Anteroposterior view of a distal femur showing sclerosis of the metaphysis and 
ossification of a soft tissue mass, with periosteal elevation indicative of aggressive 
behavior. The arrow demonstrates subperiosteal bone formation in its characteristic 
formation (“Codman’s Triangle”). Adapted from (Moore 2014).  
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Figure 10. Plain Radiographs Showing COS of the Distal Femur with Codman’s 
Triangle and Sunburst Appearance. (a) Anteroposterior and (b) lateral radiographs 
show a large mass with significant mineralization and periosteal reaction. Dotted arrows 
indicate Sunburst appearance; arrows indicate Codman’s Triangle. Adapted from (Fox 
2013).  
 
If plane radiographs suggest COS, more advanced, nuclear imaging techniques 
should be utilized to better assess the tumor and to look for metastasis. Specifically, an 
MRI of the involved bone, a complete body bone scan, and a CT scan of the chest — at a 
minimum — should be administered (Durfee 2016).  
MRI serves to determine the size of the associated soft tissue mass and its degree 
of invasion into surrounding structures. It also serves to provide a more precise indication 
of the tumor’s intramedullary extent — i.e., the portion of the central medullary canal 
being occupied by malignant tissue (Biazzo 2014). Such information is crucial for 
effective surgical management, as will be later discussed. MRI of the affected bone is 
also particularly useful in identifying skip metastases — small, discontiguous, neoplastic 
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foci that, when present, typically occur within the intramedullary canal of the affected 
bone, proximal to the primary tumor (Figure 11D). If large enough, such lesions may be 
visualized via plain radiograph, but MRI has proven to be a more sensitive and precise 
means of identification (Kager 2006). Their detection is important due to their surgical 
and prognostic implications: the portion of the bone housing the skip metastases must be 
included in surgical resection, and their presence is associated with more severe 
prognoses (Sajadi 2004).  
Whole body technetium bone scan (Figure 11C) serves to identify distant osseous 
sites where COS has developed. Areas of high bone turnover — like a region affected by 
COS — show increased technetium uptake (Durfee 2016). After identification, such 
regions can be more thoroughly probed using MRI or CT scan, depending on their 
location.  
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Figure 11. Technetium Bone Scan and MRI of Entire Femur Reveal Skip 
Metastasis. (A) Plain radiograph (x-ray) and (B) MRI showing a solitary, COS lesion of 
the distal femur. (C) Whole body bone scan and (D) MRI of the entire femur reveal 
additional skip metastasis in the diaphysis and peritrochanteric region that was not 
detected with the initial imaging (presence denoted by red box in figure (D)). Said 
finding changed the surgical plan from resection and reconstruction of the distal femur to 
(E) resection and reconstruction of the entire femur. Adapted from (Durfee 2016).  
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CT scan of the chest (Figure 12) is customary because the lungs are the most 
common site of distant metastasis in COS, present on initial diagnosis in roughly 15% of 
patients (Kim 2008). Recent studies suggest a direct correlation between the number of 
pulmonary nodules and decreased survival, and death from OS is most often the result of 
respiratory failure secondary to progressive pulmonary metastases — hence the 
importance of identification (Biazzo 2014; Fox 2013).   
 
Figure 12. CT Scan of the Chest Demonstrating Pulmonary Metastases of COS. 
Asterisks depict ossified mediastinal lesions; arrow depicts ossified right-sided lung 
nodule. Adapted from (Fox 2013).  
 
Finally, it is important to consider that even with effective use of the above-
described imaging modalities, the majority of metastatic disease goes undetected. As 
stated, roughly 15% of patients show signs of metastasis at presentation. However, it is 
estimated that an additional 60% of patients have micrometastatic disease that goes 
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unrecognized (Kaste 1999; Iwata 2016). Furthermore, with specific regard to pulmonary 
involvement, evidence points to a poor correlation between the presence of gross 
metastasis and lesions seen on imaging. In other words, palpable lesions found via 
manual exam during thoracotomy are often not present on preoperative CT, while 
nodules noted preoperatively on CT often prove to not be metastatic upon gross palpation 
and microscopic inspection (Kayton 2006). Nevertheless, CT scan remains the gold 
standard imaging technique for the lungs, highlighting the need for more precise methods 
of detection (Moore 2014). 
 
TREATMENT: PATHWAY TO ADJUVANT (POSTOPERATIVE) 
CHEMOTHERAPY    
The current standard of chemotherapy — both in terms of the specific regimen 
administered and its relative timing to surgery — has been established through a great 
number of mechanistic studies and clinical trials — with the first documented versions 
originating in the late 1960s. Before then, chemotherapy was rarely — if ever — used in 
concert with amputation to treat osteosarcoma. Unsurprisingly, survival rates were bleak. 
Then, in 1972, a study from the MD Anderson Cancer Center found a two-year survival 
rate of roughly 50% for patients treated with a combination of surgical resection and 
post-operative chemo (Misaghi 2018). Though this initial report played only a minor role 
in influencing the widespread change in practice that soon followed, it undoubtedly 
spurred the development of numerous clinical trials conducted and published during the 
1970s and 1980s that became largely responsible for the implementation of adjuvant 
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chemotherapy. For example, soon after the release of the MD Anderson report, Eilber et 
al set out to use an adequately-powered, prospective clinical trial in order to yield a 
statistically-significant and more precise response to the question that Anderson’s review 
had introduced (Misaghi 2018). Specifically, the study served to compare the outcomes 
of patients treated with surgery alone to those of patients treated with surgery followed by 
either Adriamycin, high-dose methotrexate, or a combination of bleomycin, Cytoxan, and 
actinomycin-D (Eilber 1987; Isakoff 2015; Misaghi 2018). The study was discontinued 
three years after onset, once the accumulated data had become convincing enough to lead 
the research team to believe that it would have been unethical to randomly assign patients 
to the “surgery alone” cohort. In other words, based on their confidence in the statistical 
design, execution, and consequent findings of their study, they adopted the belief that the 
combination of surgery and chemotherapy provided patients with a significantly 
increased chance of survival. In the case of the participating physicians, they amended 
their treatment strategy accordingly — as did countless other clinicians practicing at 
institutions across the world, where comparably designed clinical trials demonstrated 
improved prognosis using both single agent and combination chemotherapy (Eilber 1987; 
Isakoff 2015; Misaghi 2018). However, widespread uncertainty soon emerged, when a 
large retrospective analysis published by the Mayo Clinic reported no significant 
differences in survival between patients treated by amputation alone, and those treated by 
amputation followed by either chemotherapy or radiotherapy (Taylor 1985; Isakoff 
2015). The discrepancy between these results (obtained retrospectively) and those of 
previous studies conducted prospectively at separate institutions across the globe, drove 
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researchers at the Mayo Clinic to conduct a randomized clinical trial of their own. The 
study population consisted of thirty-eight patients who had undergone complete surgical 
resection of a primary, conventional osteosarcoma of either an extremity or the limb 
girdle. Thirty-seven of the patients had received amputations, while only one had 
undergone a limb-sparing procedure. Patients were randomly allocated to one of two 
treatment groups. Both cohorts received standard-of-care follow-up examinations, while 
only one of the two also received a high-dose methotrexate regimen. The other cohort 
served as the control and did not receive adjuvant chemotherapy. In accordance with the 
findings of their previously published retrospective analysis, no significant differences 
between the two arms were noted. However, the study was admittedly underpowered, and 
thus failed to yield a legitimate answer to the question at hand (Edmonson 1984). It did, 
however, validate the continued need for controlled clinical trials to assess the value of 
adjuvant chemotherapy in the treatment of primary COS (Isakoff 2015). In other words, it 
underscored the need to challenge previous findings that had led to substantive, yet 
perhaps misinformed and inappropriate changes in medical practice. In doing so, it 
contributed largely to the development of the Multi-Institutional Osteosarcoma Study 
(MIOS), which ultimately demonstrated — conclusively — the favorable impact of 
adjuvant chemotherapy on event-free survival (EFS) following surgical resection. 
Because this landmark trial was designed and executed in a controlled and efficient 
manner, and because of the staggering and adequately-powered results that it 
demonstrated — an 11% six-year survival rate for patients treated with surgery alone, 
versus a 61% six-year survival rate for patients treated with both surgery and multiagent 
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adjuvant chemotherapy — the latter approach became widely implemented as standard of 
care. (Link 1991; Isakoff 2015).  
 
TREATMENT: PATHWAY TO NEOADJUVANT (PREOPERATIVE) 
CHEMOTHERAPY   
Around the same time as the widespread implementation of postoperative 
chemotherapy, researchers were also experimenting with the concept of neoadjuvant 
chemotherapy. They were confident in the overall importance of chemo to the effective 
treatment of COS, and sought to determine if the timing of administration, relative to the 
time of surgical resection, could have a further impact. Exploration of the topic was also 
driven by a relatively newfound emphasis on the development of limb-sparing procedures 
to replace amputation (the traditional means of resection). During these early stages of 
prosthetic development, neoadjuvant chemo was used as a means to delay definitive 
surgery to allow for construction of custom-made endoprosthetic implants (Rosen 1982; 
Isakoff 2015; Misaghi 2018). Neoadjuvant chemo also presented the theoretical 
advantage of treating the micrometastatic disease presumed to be commonly present by 
the time of diagnosis. For many proponents of this approach, the underlying rationale was 
simple and largely intuitive: place initial focus on the systemic disease that was most 
likely present; place secondary focus on local control of the primary tumor that was 
unquestionably present (Rosen 1979; Misaghi 2018). Furthermore, it was presumed that 
this approach would facilitate uniquely precise and intricate evaluation of the efficacy of 
treatment by allowing researchers to histologically assess the extent of necrosis induced 
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in the primary tumor by preoperative chemotherapy. As many expected, a correlation was 
indeed confirmed between extent of necrosis and long-term prognosis (Bacci 1993; 
Isakoff 2015; Jones 2012; Rosen 1979; Saeter 1991). However, as will soon be explained, 
a clinical benefit to obtaining said knowledge has proved more elusive. Lastly, many 
surgical oncologists argued that precision and overall efficacy of close-margin resection 
was enhanced through administration of neoadjuvant chemotherapy — with the following 
underlying benefits commonly referenced: reduction in tumor size, enhanced clearance of 
peritumoral edema, development of a rind or pseudocapsule, and increased palpable 
firmness of the tumor (Carrle 2006; Jones 2012). However, there seems to be a paucity of 
concrete evidence to validate these claims.  
In summary, there were four major rationale for the utility of neoadjuvant 
chemotherapy that led researchers to explore its legitimacy in the treatment of COS 
during the late 20th century. The basics of each are listed in Table 3.  
Table 3. Four Major Rationale That Influenced Early Use and Further Exploration 
of Neoadjuvant Chemotherapy.  
1. NC as means to delay definitive surgery, in order to permit construction of 
custom-made prostheses used in preliminary forms of endoprosthetic 
reconstruction (limb-salvage surgery) 
2. NC as means to allow measurement of preoperative chemotherapy-induced 
tumor necrosis, thus providing a means to evaluate chemotherapeutic response 
and eradication of clinically undetectable microscopic metastatic disease 
(implications: provide patients with precise prognoses and —theoretically — 
improve prognoses through change in / addition to postoperative 
chemotherapeutic regimen in patients with poor histologic response) 
3. NC as direct means to enhance rates of EFS through immediate eradication of 
micrometastatic disease often present at diagnosis (immediate attack on 
presumed systemic disease, rather than immediate local control of known 
primary tumor)  
4. NC as means to decrease size of primary tumor and render more easily 
resectable.  
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As previously stated, neoadjuvant chemotherapy remains an element of the 
current standard of care — in combination with surgical resection and postoperative 
chemo. It would thus be reasonable to presume that significant evidence has been 
obtained over the past thirty or so years to validate each of the above-mentioned, 
underlying principles — thus confirming that this intervention does indeed present a clear 
benefit to the patients that receive it. Unfortunately, that has not been entirely the case. In 
reality, the therapeutic purpose that it serves, and the direct impact that it has on event-
free survival are far more convoluted than one would hope. For example, the first 
rationale now applies to a far lesser extent than it did originally, as modular 
endoprosthetic implants and national allograft repositories are now well-established 
(Jones 2012). The second rationale only partially pertains — instilling prognostic 
information, but not treatment guidance — as further exploration has indicated that 
neither changing nor intensifying a given chemotherapeutic regimen following a poor 
histological response results in improved survival (Rodríguez-Galindo 2002). The third 
rationale has not been validated. A pediatric oncology group set out to do so through a 
randomized clinical trial, but failed, as the study was terminated prematurely after years 
of insufficient patient accrual. Lack of enrollment most likely stemmed from the fact that 
most surgeons were generally unwilling to assign patients to the immediate surgery 
cohort (control) over the neoadjuvant chemotherapy cohort, because they believed so 
firmly in the fact that the latter approach made for simpler and more effective resection 
(Jones 2012). Though the study was underpowered and failed to reach significance, the 
results pointed towards improved survival in the immediate surgery arm (Goorin 2003). 
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Naturally, said findings did little, if anything at all, to slow the acceptance of neoadjuvant 
chemotherapy as at least potentially beneficial. Lastly, a more recent study served to test 
the fourth rationale — that osteosarcomas are rendered more easily resectable following 
neoadjuvant chemo. Its results indicate that this thinking is more anecdotal than evidence 
based, as some tumors improved with regard to surgically critical anatomy, while others 
worsened. In the end, the authors of the study made sure to emphasize that they were not 
advocating a change in the standard practice of providing neoadjuvant chemotherapy 
based on their inconsistent findings (Jones 2012).  
 
Though research has failed to demonstrate that combined preoperative and 
postoperative chemotherapy yields survival benefits relative to adjuvant chemotherapy 
alone, it remains an element of the current standard of care for a number of reasons. For 
one, it allows time for surgical planning. Though the extent of time once required for 
custom fitting of endoprosthetic implants is no longer necessary, additional time for more 
extensive evaluation of various imaging modalities still provides benefit. Additionally, 
neoadjuvant chemotherapy potentially facilitates resection of the primary tumor; and 
lastly, it undoubtedly allows for precise in vivo assessment of the effects of systemic 
treatment, thus serving as an extremely precise prognostic indicator (Bielack 2002; 
Goorin 2003). 
 
TREATMENT: PATHWAY TO LIMB-SPARING SURGERY  
 
 Historically, amputation was considered necessary to effectively eliminate a 
primary tumor. The introduction of chemotherapy, coupled with advances in imaging and 
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reconstructive techniques, allowed for a shift in thinking and practice. Today, roughly 85-
90% of cases of high-grade, appendicular OS can be effectively resected and 
reconstructed with preservation of the affected limb (Bacci 2001; Bacci 2006; Ferrari 
2001). Limb-salvage is preferred because it provides better function and equal if not 
better survival than amputation (Finn 1991; Stevenson 2016; Han 2016; Ferrari 2001). 
Amputation is thus almost exclusively reserved for tumors deemed non-resectable due to 
extensive soft-tissue and neuromuscular contamination (Durfee 2016). 
Limb-salvage procedures consist of resection followed by reconstruction. 
Effective resection entails complete removal of the primary tumor and all clinically 
detectable metastases with a wide enough margin to ensure that no residual disease 
remains (Durfee 2016). Numerous preoperative imaging modalities — primarily bone 
and CT scan — allow the surgeon and team to determine the necessary amount of bone to 
removed, depending on the size of the lesion. It is suggested that the bone be 
osteotomized roughly 6-7 cm proximal or distal to the respective border of the lesion, in 
order to ensure clear margins (Misaghi 2018). As stated, imaging serves to delineate the 
borders of said lesion, and adequacy of margins has been confirmed as a critical factor in 
preventing recurrence of disease (Bacci 2006; Malawer 1989).  
Computer aided navigation has recently emerged as a means to enhance accuracy 
of osteotomy. Khan et al conducted a study on six pairs of matched cadaver femurs, 
comparing accuracy of resection performed manually to that performed using computer-
aided software and custom jigs. A greater extent of deviation from the preoperative plan 
was noted in the manually resected femurs, indicating that computer-aided navigation can 
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enhance precision of surgical resection (Figure 13) (Khan 2013). 
 
 
Figure 13. Manual VS Computer-Navigated, Custom-Jig Resection. Postresection 
images superimposed on preoperative plan for (a) manually resected specimen and (b) 
custom-jig resected specimen. Preoperative plan = red lines; Area of ocean blue = region 
of deviation. Notice the complete absence of ocean blue area in the custom-jig resected 
specimen, denoting near perfect adherence to preoperative plan. Adapted from (Khan 
2013).  
 
 Reconstruction follows resection —except when the primary tumor is located in a 
non-weight-bearing bone, in which case removal does not induce a functional deficit that 
must be corrected for (Durfee 2016). Today, endoprosthetic and biological replacement 
serve as the two primary options for reconstruction of weight-bearing bones following 
resection of a conventional osteosarcoma. Endoprosthetic reconstruction (Figures 14 and 
15) serves as the surgery of choice in the vast majority of medical centers (Harrison 
2018). Better functional outcomes, cosmetic, and psychological benefits have been 
associated with endoprosthetic reconstruction when compared to amputation and 
	 42 
rotationplasty (a surgical procedure in which a large portion of the distal femur and 
proximal tibia is resected, before the lower leg, ankle and foot are rotated 180 degrees, 
and the distal tibia re-attached to the proximal femur at the initial site of resection — the 
ankle joint effectively becomes the knee joint, and retains the ability to flex and extend, 
thus restoring function with use of a lower-leg prosthesis) (Hillmann 1999). Within the 
category of endoprosthetic implants exist the following sub-categories: custom-made, 
modular, and expandable implants that are reserved for skeletally immature patients. The 
first endoprosthetic models were custom-made. Modular implants (i.e., those that are 
manufactured in bulk — and not on a patient by patient basis like their custom-made 
predecessors — with adjustable parts that allow for custom-fitting) have been the more 
commonly used variant since the 1990s. They are less expensive, require less time and 
effort to construct, and have demonstrated improved survivorship when compared to their 
custom-made counterparts, while still permitting a degree of customization that can be 
manipulated intraoperatively based on the patient’s anatomy (Schwartz 2010; Durfee 
2016). Expandable prostheses (Figure 15) are used following growth-plate resection in 
children. Interval lengthenings of typically 1-2 cm are performed to match the natural 
growth of the healthy contralateral extremity (Finn 1991). The primary drawbacks of all 
endoprosthetic variants are a lifelong risk of infection — due to the nonbiological nature 
of the implant — and complications pertaining to mechanical failure. Recent studies have 
reported typical implant survivorship of roughly 80% at five years, and 60% at ten years 
of follow-up (Durfee 2016). A particular study with over twenty years of follow-up 
conducted by the Royal Orthopaedic Hospital Oncology Service in England 
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retrospectively reviewed outcomes following endoprosthetic reconstruction in 661 
patients receiving either custom made or modular implants. Children that received 
expandable implants were excluded. The study presented the following findings: overall 
implant survival at ten years of 75%; overall limb-salvage rate at twenty years of 84%, 
with 34% of patients requiring revision surgery due to mechanical failure, infection, and 
locally recurrent disease (Jeys 2008). A more recently published study with a mean 
follow-up of 29.4 years demonstrated that given a long enough life-span, there is an 
almost inevitable need for revision surgery following first-generation endoprosthetic 
reconstruction. Perhaps more importantly though, with revision came maintenance of 
limb-salvage and function in the vast majority of cases (Grimer 2016).  
Biological replacement serves as the other major reconstructive option following 
resection. Though endoprosthetic reconstruction is now more commonly utilized, 
massive bone allografts (Figure 16) serve as a particularly useful option in the setting of 
diaphyseal tumors, where they allow preservation of both the physis and the opposing 
joint surface (Harrison 2018). In general, biological replacement has the benefit of 
enhanced reinsertion of associated soft-tissue structures and better preservation of 
anatomy. However, it is associated with a host of well-known and widely accepted 
shortcomings that seem to have led to the ascendancy of endoprosthetic reconstruction — 
for example, rates of nonunion and fracture are relatively high following allograft 
reconstruction (Donati 2000; Durfee 2016; Gebhardt 1991; Harrison 2018; Misaghi 
2018). 
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Figure 14. Endoprosthetic Reconstruction of the Proximal Tibia. (A) X-ray images 
show an aggressive lesion with abundant osseous matrix. (B) Resection being performed 
to preserve neurovascular bundle. (C) Reconstruction via proximal tibia endoprosthesis 
with (D) gastrocnemius muscle flap for soft-tissue coverage. (E, F) Resected tumor 
specimen showing gross pathology. Adapted from (Durfee 2016).  
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Figure 15. Endoprosthetic Reconstruction of the Distal Femur and Proximal Tibia 
with Expandable Implant. Notice the interval lengthening performed to match the 
natural growth of the healthy contralateral extremity. Adapted from (Arteau 2015). 
 
 
Figure 16. Massive Fibular Allograft Reconstruction of the Distal Femur. Adapted 
from (Biazzo 2014) 
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TREATMENT: SUMMARY OF CURRENT MULTI-MODAL APPROACH AND 
RECENT ATTEMPTS TO IMPROVE OUTCOMES IN POOR RESPONDERS  
 
In summary, limb-sparing surgical resection of all gross disease, in combination 
with pre and post-operative systemic chemotherapy to control micro-metastatic disease, 
became the standard of care for patients with COS in the 1980s. It remains so today.  
Neoadjuvant chemotherapy typically consists of two cycles of MAP over the 
course of 10 weeks prior to surgical resection. (MAP = High-dose methotrexate with 
leucovorin rescue (HDMTX), doxorubicin, and cisplatin) (Anninga 2011). Adjuvant 
MAP is then typically resumed within 3 weeks following surgery, as analyses have 
shown that delays longer than this are associated with an elevated risk of recurrence 
(Meyers 2005; Imran 2009). Today, this multi-modal approach to treatment yields a 5-
year EFS of roughly 70% for patients with localized presentation. In the roughly 30% of 
patients in which the disease recurs within 5 years following initial treatment, subsequent 
5-year survival drops to less than 20% (Harrison 2018).  
Histologic response to preoperative chemotherapy has been confirmed as the 
single most precise independent prognostic indicator of EFS (Bielack 2002). A good 
histologic response is generally considered greater than 90% necrosis of the primary 
tumor — or in other words, less than 10% tumor viability following neoadjuvant MAP. 
Numerous studies have demonstrated that said patients have decreased rates of both local 
and systemic recurrence, and increased rates of disease-free survival (Figure 17) (Bacci 
1993; Provisor 1997; Winkler 1988; Andreou 2011). In fact, a landmark study conducted 
by the Children’s Cancer Group at Methodist Hospital of Indiana reported a greater than 
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90% 5-year EFS in good responders, compared to a 50-60% EFS in patients that received 
a poor histologic response post-MAP (Provisor 1997). A more recent study conducted in 
2015 produced similar findings: O’Kane et al. retrospectively reviewed the outcomes of 
97 patients with COS who received MAP followed by surgical resection. Those with 
greater than 90% necrosis of the primary tumor had an 82% five-year survival rate, while 
those with less than 90% tumor necrosis had a 68% five-year survival rate (O’Kane 
2015). 
 
 
Figure 17. Histological Response to Neoadjuvant Chemotherapy and Survival. X-
axis: % tumor necrosis. Y-axis: years of survival following neoadjuvant chemotherapy, 
surgical resection, and postoperative chemotherapy. Grades 1-6 represent increasing 
tumor viability (i.e., decreasing tumor necrosis) following neoadjuvant chemotherapy. In 
other words, a patient with a grade 6 tumor would be considered a poor responder. The 
relationship between a poor response to preoperative chemotherapy and a decreased 
chance of long-term survival are thus shown. Adapted from (Carrle 2006).  
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Extensive effort has thus been directed towards improving outcomes in this cohort of 
poor responders. For example, multiple cooperative clinical trials have explored the 
effect of intensification of adjuvant chemotherapy, albeit, with limited success. (Marina 
2016; Schwartz 2016; Meyers 2005). Most recently, the EURAMOS-1 study – a joint 
collaboration between European and American groups – sought to determine whether the 
addition of high-dose ifosfamide and etoposide (I/E) to adjuvant chemotherapy could 
improve outcomes for this sub-group following surgical resection. Unfortunately, no 
statistically significant difference in EFS was seen, leading the authors of this study to 
conclude that intensification of adjuvant chemotherapy via the addition of high-dose I/E 
does not improve outcomes for those that respond poorly to neoadjuvant MAP (Marina 
2016). EURAMOS-1 also sought to evaluate the role of the cytokine interferon alfa-2b in 
the treatment of high-grade OS. Specifically, the study assessed whether addition of this 
cytokine could improve outcomes for patients with a good histological response 
following surgical resection, by randomizing said good responders to receive adjuvant 
MAP alone (control / current standard of care) versus adjuvant MAP coupled with 
interferon alfa-2b — which had shown to elicit antiproliferative and pro-apoptotic effects 
in pre-clinical models of OS (Whelan 2010). Unfortunately, in vivo, no statistically 
significant difference was noted between the two arms (Bielack 2015). 
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Figure 18. EURAMOS 1 Treatment Regimen. Randomization of good responders to 
receive either adjuvant MAP alone or adjuvant MAP + interferon alfa-2b (top); 
randomization of poor responders to receive either adjuvant MAP alone or adjuvant MAP 
+ I/E. Adapted from (Carrle and Bielack 2006).  
 
Despite these results, considerable interest remains in the potential of 
immunomodulating strategies to improve outcomes for patients with COS. For example, 
muramyl tripeptide phosphatidylethanolamine (MTP-PE) is a synthetic analog of the 
Bacille Calmette Guerin bacterial cell wall that can be encapsulated into liposomes. In 
mouse models, it was found to activate macrophages and monocytes in the lungs to 
become tumoricidal toward osteosarcoma cells (Meyers 2014; Harrison 2018). Based on 
its potential demonstrated through pre-clinical research, the Children’s Cancer Group and 
Pediatric Oncology Group decided to explore the utility of this molecule in vivo in 
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patients with newly diagnosed, localized COS. Specifically, the Group conducted a 
randomized, phase III clinical trial designed to evaluate the addition of high-dose 
ifosfamide and MTP-PE to MAP chemotherapy in patients with nonmetastatic 
osteosarcoma. While the addition of ifosfamide showed no benefit, the addition of MTP-
PE to MAP adjuvant therapy yielded a trend toward improved EFS (Meyers 2014). 
Accordingly, MTP-PE has been incorporated into therapeutic protocols for selected 
patients at medical centers around the world. In the US, the drug has not been approved 
by the FDA due to questions regarding the statistical design and consequent findings of 
the above-described study. Regardless, several institutions in the US have incorporated 
the drug into the treatment protocols of eligible patients via compassionate use protocols 
that work in concert with the FDA (Harrison 2018).  
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CONCLUSIONS AND FUTURE DIRECTIONS 
Outcomes for patients with newly diagnosed COS have plateaued since the 
development of adjuvant chemotherapy and limb-sparing surgical techniques. Though the 
majority of patients fair well following administration of current multi-modal treatment, a 
significant number respond far less favorably — with extent of tumor necrosis post-
neoadjuvant MAP serving as the most reliable prognostic indicator. Put simply, disease 
frequently recurs in patients who respond poorly to preoperative chemotherapy; and 
when it does, it results in a marked reduction in long-term survival. Unfortunately, a 
clinical application for this prognostic correlation has yet to be found. Intensification of 
systemic therapy with addition of I/E proved unsuccessful in improving outcomes for this 
subgroup of patients; and though the incorporation of immunotherapy therapy with MTP-
PE showed some promise — and has thus been incorporated into the treatment protocols 
of select patients around the world —the true utility in improving long-term outcomes 
remains largely up for debate. It is clear that novel modes of systemic treatment are 
needed to enhance overall efficacy of care. In order do so, it must first be determined why 
certain patients prove poorly responsive to the same treatment that proves highly-
effective in others. In other words, what — at the molecular level — is allowing 
recurrence and metastasis following initial treatment? Or more specifically, what genetic 
and/or proteomic anomalies are unique to these patients and their primary and recurrent 
tumors? In order to answer these questions — among many others — extensive genetic 
sequencing and immunoprofiling will have to be conducted on resected tumor tissue. 
Great effort is now being made in exactly that context — both by individual institutions 
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including the MD Anderson Cancer Center, and cooperative groups such as the Sarcoma 
Alliance for Research Through Collaboration — to harvest primary, recurrent, and 
metastatic specimens for subsequent analysis (Harrison 2018). Ideally, this work will 
allow identification of novel targets — for example, particular pathways that drive 
chemotherapeutic resistance and metastasis — that will then be exploited 
pharmacologically in order to enhance the specificity and overall effectiveness of COS 
treatment for poor responders. 
At the same time, it seems necessary to further scrutinize and perhaps even 
rethink the current approach to care — particularly in regard to the use of neoadjuvant 
chemotherapy. As previously discussed, clinical research has failed to demonstrate that it 
presents a survival advantage when compared to immediate surgery followed by adjuvant 
MAP. Modular prosthetics and allograft bone banks have mitigated the need to prolong 
the preoperative period for surgical planning; clinical utility of the quantification of 
tumor necrosis has yet to be discovered; and very little evidence actually suggests that 
efficacy of local resection is enhanced through administration of neoadjuvant MAP. On 
the other hand, there seems to be a clear benefit to foregoing preoperative chemotherapy 
and proceeding immediately to surgery in the setting of newly diagnosed, localized COS. 
Much of the existing literature regarding this disease points to the thinking that novel 
therapies targeted specifically for the recurrent and/or metastatic patient will only arise 
through a deeper understanding of the unique biology underlying said processes. In order 
to develop this understanding, a vast quantity of primary, chemotherapy-naïve tumors 
must be harvested and analyzed. The current standard of care makes this virtually 
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impossible, as the majority of newly-diagnosed patients receive neoadjuvant MAP prior 
to surgery, so that by the time of collection, the molecular composition of the tumor has 
already been drastically altered (Harrison 2018). Thus, a shift in approach from 
neoadjuvant MAP to immediate surgery would — theoretically, at least — present no 
additional cost to the patient himself, while bestowing the advantage of ultimately 
enhanced care through improved biological understanding. However, debate remains 
concerning the former claim, as many experts in the field feel that immediate surgery 
would compromise EFS in the majority of patients — largely intuitively, it seems, as the 
paucity of supporting evidence is undeniable. Nevertheless, neoadjuvant MAP remains 
standard of care. Whether novel research will drive a shift in thinking and practice in the 
years to come, remains to be seen.  
In regard to the link between translational and clinical research pertaining to OS, a 
shift in strategy has already been put in place by the Children’s Oncology Group. 
Hopefully, it will facilitate the implementation of novel modes of treatment that lead to 
improved outcomes. Essentially, the group has taken an aggressive new approach to 
evaluating promising molecular agents — like those discussed in the previous section 
pertaining to the molecular genetics and pathophysiology of OS — through phase II 
clinical trials in the high-risk recurrent OS population. Agents associated with promising 
pre-clinical data will be administered in vivo, and their impact on progression free 
survival compared to a historical control of 12% at four months following treatment. 
Agents that yield improvement will then be further tested through larger, randomized, 
phase III clinical trials (Harrison 2018; Lagmay 2016). Again, the overarching goal is to 
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identify clinically beneficial therapies. At the very least, the strategy should allow 
researchers to eliminate inactive agents that showed misleading pre-clinical promise, 
without exhausting resources through unnecessary phase III trials.  
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